BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35325631)

  • 1. Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients.
    Sun X; Song Z; Jiang H; Ma Y; Chen M
    Clin Imaging; 2022 Jun; 86():31-37. PubMed ID: 35325631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis.
    Shu Y; Xu W; Su R; Ran P; Liu L; Zhang Z; Zhao J; Chao Z; Fu G
    Front Immunol; 2023; 14():1251645. PubMed ID: 37799725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors.
    Sun Z; Wang S; Du H; Shen H; Zhu J; Li Y
    Invest New Drugs; 2021 Jun; 39(3):891-898. PubMed ID: 33428078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and outcome of immune checkpoint-induced pneumonitis in oncology patients with history of pulmonary disease.
    Allen E; Umoru G; Ajewole V; Bernicker E
    Front Oncol; 2023; 13():1283360. PubMed ID: 37941544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep learning predicts immune checkpoint inhibitor-related pneumonitis from pretreatment computed tomography images.
    Tan P; Huang W; Wang L; Deng G; Yuan Y; Qiu S; Ni D; Du S; Cheng J
    Front Physiol; 2022; 13():978222. PubMed ID: 35957985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy.
    Barrón F; Sánchez R; Arroyo-Hernández M; Blanco C; Zatarain-Barrón ZL; Catalán R; Ramos-Ramírez M; Cardona AF; Flores-Estrada D; Arrieta O
    Front Oncol; 2020; 10():570233. PubMed ID: 33117699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are immune checkpoint inhibitors safe and effective in lung cancer patients with pre-existing interstitial lung disease?
    Zhu L; Gao R; Li H; Zheng Y; Yang J
    Immunotherapy; 2024 Apr; 16(7):465-480. PubMed ID: 38511241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
    Yamagata A; Yokoyama T; Fukuda Y; Ishida T
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
    Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
    Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective study of combination therapy with glucocorticoids and pirfenidone for PD-1 inhibitor-related immune pneumonitis.
    Li Y; Huang H; Ye X; Zeng B; Huang F; Chen L
    Medicine (Baltimore); 2024 Apr; 103(16):e37808. PubMed ID: 38640289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia.
    Isobe K; Nakamura Y; Sakamoto S; Tomii K; Takimoto T; Miyazaki Y; Matsumoto M; Sugino K; Ichikado K; Moriguchi S; Yamaguchi K; Baba T; Ozasa H; Igata F; Anabuki K; Homma S; Date H; Suda T; Kishi K
    ERJ Open Res; 2024 Mar; 10(2):. PubMed ID: 38444654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
    Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
    BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies.
    Matsumoto K; Shiroyama T; Kuge T; Miyake K; Yamamoto Y; Yoneda M; Yamamoto M; Naito Y; Suga Y; Fukushima K; Koyama S; Iwahori K; Hirata H; Nagatomo I; Takeda Y; Kumanogoh A
    Transl Lung Cancer Res; 2022 Sep; 11(9):1835-1846. PubMed ID: 36248332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers.
    Nobashi TW; Nishimoto Y; Kawata Y; Yutani H; Nakamura M; Tsuji Y; Yoshida A; Sugimoto A; Yamamoto T; Alam IS; Noma S
    Br J Radiol; 2020 Nov; 93(1115):20200409. PubMed ID: 32783627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
    Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1
Antibody-Safety and Effectiveness of Pirfenidone].
    Yu H; Li J; Yu L; Cheng X; Han X; Zhang X
    Zhongguo Fei Ai Za Zhi; 2021 Jul; 24(7):519-525. PubMed ID: 34134189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical and chest CT features of immune checkpoint inhibitor-related pneumonitis].
    Zhang Q; Zhao SJ; Wang SH; Tao XL; Wu N
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):182-187. PubMed ID: 36781241
    [No Abstract]   [Full Text] [Related]  

  • 18. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
    Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
    AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
    [No Abstract]   [Full Text] [Related]  

  • 19. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
    Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
    J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.